Skip to Main Content

Evaluating ARIA in the treatment of Alzheimer’s disease with neuroimaging AI

By Cortechs.ai

2 mins

In the realm of medical research, the development of cutting-edge technologies has revolutionized our understanding and treatment of various diseases.

 

One such field is artificial intelligence (AI) neuroimaging detection and quantification, which may significantly impact the surveillance of Amyloid-Related Imaging Abnormalities (ARIA) that can be a side effect of recently approved pharmaceuticals being used to treat Alzheimer’s disease.


Share

Topic
Product updates
Disease
Alzheimer's disease Neurodementias
Solution
NeuroQuant ARIA

Insights

5 mins

Oct 28 2024

How AI Will Transform Healthcare Students’ Experience

EDITORIAL: The potential applications of AI are vast, and how can early exposure to these technologies better prepare healthcare students?

Cortechs.ai news

4 mins

Oct 28 2024

The Benefits and Limitations of Neuroimaging AI Software in Traditional Diagnostic Workflow

Software like NeuroQuant offers powerful solutions that complement traditional diagnostic methods, enhancing both speed & accuracy

Cortechs.ai news

2 mins

Oct 14 2024

RANO 2D and 3D Measurements as a Companion Diagnostic Tool in NeuroQuant Brain Tumor

NeuroQuant’s Brain Tumor module automates RANO 2D and 3D measurements, providing clinicians with precise data to improve treatment planning and patient outcomes

Industry news

View our insights